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ABSTRACT
Introduction: Bevacizumab addiction to triplet chemotherapy, according to FIr-B/
FOx schedule, as first-line treatment in young-elderly metastatic colorectal CANCER 
(MCRC) patients may be more effective. Tailored treatments show worse clinical 
outcome in unfit patients.
Methods: Elderly patients were clinically evaluated according to age and 
comorbidity (Cumulative Illness Rating Scale) to select FIr-B/FOx regimen in fit or 
tailored treatments in unfit elderly. Limiting toxicity syndromes (LTS) were evaluated.
Results: At 17 months follow-up, in 28 young-elderly patients treated with first line 
FIr-B/FOx: objective response rate (ORR) 79%, progression-free survival (PFS) 11 months, 
overall survival (OS) 21 months. Clinical outcome was not significantly different according 
to KRAS genotype. G3-4 toxicities were diarrhea 21%, mucositis 11%, neutropenia 11%. 
LTS were 46%, significantly more multiple than single site. At 8 months follow-up, in 37 
unfit patients: ORR 37%, PFS 7 months, OS 13 months. PFS was significantly different in 
KRAS wild-type compared to mutant patients, while not OS. PFS and OS were significantly 
worse in KRAS c.35 G > A compared to wild-type and/or other mutant.
Conclusions: Careful decision-making process including evaluation of patient’s 
fitness, and individual safety should be included to select FIr-B/FOx intensive first 
line regimen in young-elderly MCRC patients. KRAS, and specifically c.35 G > A mutant 
genotype, may significantly affect clinical outcome in patients unfit for FIr-B/FOx.
INTRODUCTION
Different treatment options and lines of medical 
treatment in metastatic colorectal cancer (MCRC) patients 
are currently tailored according to fitness (age, performance 
status (PS), comorbidities), metastatic extension (liver-
limited (L-L) or other/multiple metastatic (O/MM)), and 
RAS genotype [1–7]. First line regimens, consisting of 
triplet chemotherapy, or bevacizumab (BEV) or cetuximab 
or panitumumab in addiction to doublet chemotherapeutic 
drugs, showed overlapping activity and clinical outcome 
in phase III trials: objective response rate (ORR) 39%-
68%, progression-free survival (PFS) 7.2-10.6 months, 
and overall survival (OS) 19.9-26.1 months [3, 5, 7, 8, 
1]. In ‘fit’ patients, these treatment options in first-line 
setting, integrated with secondary liver metastasectomies, 
significantly increased clinical outcome over doublet 
chemotherapy. More intensive triplet chemotherapy plus 
BEV can further achieve ORR 82%, liver metastasectomies 
26%, PFS 12 months, OS 28 months [2-4, 9, 10, 6]. In L-L 
disease, metastasectomies were 54% and clinical outcome 
was significantly improved, particularly in KRAS wild-type 
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patients [4, 6]. The selection among intensive and more 
effective or tailored first-line medical treatment, with a 
proper balance between expected efficacy and safety, also 
according to prognostic parameters (extension of metastatic 
disease in terms of involved sites (liver-limited, other/
multiple metastatic sites), KRAS genotype) represents a 
major challenge in clinical management of MCRC patients.
MCRC patients are prevalently elderly but often under-
treated in clinical practice, and usually underrepresented 
in clinical trials. They require a decision-making process 
combining the evaluation of fitness, according to co-
morbidity, functional, and nutritional status [11], and selection 
of proper medical treatment with increasing effectiveness 
weighed by non-limiting toxicity and maintained quality 
of life (QoL). Clinical characteristics limiting fitness for 
intensive medical treatments are elderly status (>=75 
years), PS ≥2, and/or comorbidities. Retrospective studies 
showed similar safety and efficacy in fit elderly compared 
to younger patients [12–14]. Elderly patients benefited 
from 5-fluorouracil (5-FU) [15–17], irinotecan (CPT-
11)-containing chemotherapy [18, 19], FOLFOX [20] as 
younger patients [20–22]. In fit patients ≥70 years, 5-FU 
reported ORR 23.9%, PFS 5.5 months, OS 10.8 months 
[15]. The same clinical benefit and tolerability were reported 
from CPT-11-containing chemotherapy [18]; age did not 
represented an independent prognostic factor correlated 
to OS [19]. FOLFOX conferred a significantly improved 
relative benefit independently from age [20]. In old-elderly 
and younger patients treated with FOLFOX, (OPTIMOX1 
trial), activity and efficacy data were comparable: ORR 
59%, median PFS 9.0 months, and median OS 20.7 
months [21]. In the FOCUS2 trial, specifically designed to 
prospectively evaluate first line reduced-dose (80%) of 5-FU 
or capecitabine added or not to OXP in old-elderly and/or 
frail patients, OXP addition did correlated with a benefit in 
terms of OS and above all PFS (5.8 vs. 4.5 months, p 0.07), 
the primary endpoint of the study, but with a significantly 
improved ORR (35% vs 13) [22]; combination therapy did 
not significantly modify safety profile, but showed worse 
QoL. Treatment efficacy was consistent across subgroups, 
including age, when BEV was combined with CPT-11-
based therapy [23]. In fit elderly patients, BEV addition 
to 5-FU-containing chemotherapy conferred significantly 
longer PFS (9.2 months) and OS (17.4-19.3 months) [24, 
25]. In BRiTE and BEAT trials, which are two large trials 
that evaluate the association between doublet chemotherapy 
plus bevacizumab, PFS was not different (about 10.0 
months); median OS decreased with age [25, 26]. The use 
of bevacizumab plus chemotherapy in this setting of patients 
was also investigated in other two phase II studies. The results 
of AXELOX [43] and BECOX [44] trials suggested that the 
combination of bevacizumab to doublet chemotherapy could 
be an acceptable first line option for older mCRC patients.
No impact on PFS and OS was observed by age and/or 
comorbidities in patients treated with FOLFOX or FOLFIRI 
added or not to cetuximab [27]. Addition of panitumumab to 
FOLFOX showed no clear benefit in PFS in elderly patients, 
and with PS 2 [29]. PS 1 compared to PS 2 significantly 
modified clinical outcome, regardless of medical treatment 
administered, as showed in a meta-analysis: ORR 43.8% 
vs 32%, PFS 7.6 vs 4.9 months, OS 17.3 and 8.5 months, 
respectively [30]. In the phase III randomized trial comparing 
FOLFOXIRI with FOLFIRI, age was not a significant 
parameter affecting activity and efficacy; elderly patients 
showed median OS 19.9 and 16.9 months, respectively [31, 
32]. Activity was significantly lower in older patients enrolled 
in the FOLFOXIRI arm [32]; no differences were reported 
in PFS and OS. Patients who underwent metastasectomies 
didi not showed significantly more morbidity and/or 
mortality, independently from age. Patients with PS 2 showed 
significantly worse clinical outcome in both FOLFIRI and 
FOLFOXIRI arm [31, 32].
Recent retrospective analyses reported by our group, 
evaluating clinical outcome and safety of first-line FIr-B/
FOx intensive regimen in fit young-elderly MCRC patients 
[2, 33], or tailored medical treatments in patients unfit, 
due to age and/or comorbidities [7], point out the need to 
integrate the evaluation of patient’s fitness and selection 
of first line medical treatment in a proper decision-making 
process in elderly MCRC patients.
RESULTS
Effectiveness and safety of triplet chemotherapy-
based intensive regimens in elderly MCRC 
patients
Intensive triplet chemotherapy
HORG-FOLFOXIRI schedule proposed by Soug-
lakos et al. [32], characterized by reduced projected DI (pDI) 
of CPT-11 (65 mg/m2/w), OXP (32.5 mg/m2/w), associated 
to bolus plus continuous infusion 5-FU (pDI 1000 mg/m2/w; 
received dose intensity (rDI) 880 mg/m2/w (88%)) failed to 
confirm significantly improved clinical efficacy compared to 
FOLFIRI in unresectable MCRC patients [3, 32]. Different 
patients’ selection, DI of drugs, and/or 5-FU administration 
modality may justify these results [5]. Elderly patients were 
prevalently enrolled (56%, median age 66 years) and PS was 
poorer; elderly patients >70 years and also >75 years with an 
ECOG PS 1 or higher were enrolled. Elderly patients were 
not evaluated for comorbidity and functional status. The 
study reported a significantly higher incidence of toxicity in 
older patients and those with PS 2; PS 2 patients showed a 
significantly lower median OS and PFS, in both arms [31, 5].
In an unplanned subgroup evaluation of the phase 
III study, prognostic relevance of elderly status in both 
FOLFIRI and FOLFOXIRI treated patients was evaluated 
[32], and clinical outcome was not significantly different. 
In elderly patients treated with FOLFIRI, compared with 
younger, no significantly different activity and efficacy 
data were reported: ORR 31.7%; time to tumor progression 
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(TTP) 6.2 months; median OS 17.8 months (Table 1). In 
patients treated with FOLFOXIRI, ORR was significantly 
lower in elderly compared to younger patients, 32% vs 52% 
(p = 0.03); however, TTP (8.5 vs. 9.6 months, respectively; 
p = 0.54) and median OS (19.9 vs. 23 months, respectively; 
p = 0.47) were not significantly different.
HORG/FOLFOXIRI intensive regimen showed 
a worse safety profile compared to FOLFIRI, with 
significantly more dose reductions and treatment delays; 
in elderly compared with younger patients, significantly 
more dose reductions (9.5% vs 4.8%, p = 0.01), treatment 
delays (17.7% vs 9.7%, p = 0.05), particularly due to 
toxicity were reported (11.8% vs 7%, p = 0.05). In the 
FOLFIRI arm, dose reductions (4.2% vs 2.4%, p = 0.06) 
and treatment delays were not different. However, there 
was no significantly different rDI of drugs in elderly 
compared with younger patients, in both FOLFOXIRI and 
FOLFIRI arms.
Grade 3-4 diarrhea was significantly more 
prevalent in elderly, compared to younger patients, in 
both chemotherapy regimens (p = 0.005 in FOLFIRI, p 
= 0.017 in FOLFOXIRI arm) [32]. Moreover, diarrhea 
was significantly more frequent in elderly patients treated 
with FOLFOXIRI, compared with patients treated with 
FOLFIRI regimen (Table 2). No other significantly 
different grade 3/4 toxicities were reported, according to 
elderly status. No other significantly different grade 3/4 
hematologic or non-hematologic toxicities were reported 
between young elderly (65 -75 years) and old elderly 
patients (>=75 years).
Intensive triplet chemotherapy plus bevacizumab, 
FIr-B/FOx, in young-elderly
We retrospectively evaluated consecutive young-
elderly patients 65 to 75 years enrolled in the previously 
reported phase II trial [2] and in the expanded clinical 
program of first-line FIr-B/FOx treatment [33], from 
March 2006 to November 2011: 5-FU 900 mg/m2, 
12h-timed-flat-infusion, 2 days weekly; CPT-11 160 mg/
m2/BEV 5 mg/kg or OXP 80 mg/m2, weekly alternating. 
Cumulative Index Rating Scale (CIRS) was used to 
evaluate the comorbidity status, and only patients with 
primary and intermediate CIRS stage were enrolled 
[10]. Primary CIRS stage consisted of: independent 
Instrumental Activity of Daily Living (IADL), and absent 
or mild grade comorbidities; intermediate CIRS stage 
consisted of dependent or independent IADL, and less 
than 3 mild or moderate grade comorbidities. Patients 
with secondary CIRS stage, consisting of more than 3 
comorbidities or a severe comorbidity, with or without 
dependent IADL, were not enrolled. To discriminate 
individual safety, limiting toxicity syndromes (LTS), 
consisting of a LT associated or not to other limiting or 
G2 toxicities, were evaluated [2, 33]. LTS were classified 
as limiting toxicity syndromes single site (LTS-ss), 
characterized by the LT alone, and limiting toxicity 
syndromes multiple sites (LTS-ms), ≥ 2 LTs or a LT 
associated to other G2-3, non-limiting toxicities.
Young-elderly patients were 28 (42%) among 
overall MCRC patients enrolled fitting for FIr-B/FOx 
intensive treatment, according to inclusion criteria, 
WHO PS 0 89%, CIRS primary/intermediate. At a 
median follow-up of 17 months, ORR was 79%, liver 
metastasectomies 18% (37.5% in L-L patients), median 
PFS 11 months (3-78+), median OS 21 months (6-78+) 
(Table 1). Among 13 KRAS wild-type patients, ORR was 
92%, liver metastasectomies 23% (50% in L-L patients), 
median PFS 14 months (4-78+ months), median OS 38 
months (8-78+ months). Among 13 KRAS mutant patients, 
ORR was 77%, liver metastasectomies 15%, (20% in L-L 
patients), median PFS 7 months (3-69+ months), median 
OS 19 months (6-69+ months). Neither PFS nor OS were 
significantly different in KRAS wild-type compared with 
mutant patients, according to log-rank test. No BRAF 
mutations were detected.
Median rDI per cycle were 80% of the pDI for 
all the associated drugs. G3-4 toxicities were (Table 2): 
diarrhea 21%; stomatitis/mucositis 11%; asthenia 11%; 
neutropenia 11%. The prevalent toxicity was diarrhea, 
G2-G3 50%, similarly to non elderly [2]. LTS were 
observed in 13 out of 28 young-elderly patients (46%): 
LTS-ms, 11 patients (39%); LTS-ss, 2 patients (7%). 
LTS-ms were characterized by: LT associated to other 
G2-3, non-limiting toxicities, 9 patients (32%); ≥ 2 LTs, 
2 patients (7%). LTS were significantly represented 
by LTS-ms compared to LTS-ss (chi square 3.832, p = 
0.05), with respect to non elderly patients. LTS were: 
G2-3 diarrhea-associated, 9 patients (69.2%), 8 LTS-
ms and 1 LTS-ss; G3 mucositis associated with G3 
erythema, 1; G3 stomatitis/mucositis and G2 asthenia, 
1; G2 neutropenia for > 2 weeks with G2 nausea, 1; G3 
asthenia, 1.
Table 1: Activity and efficacy in elderly MCRC patients
FIr-B/FOx FOLFOXIRI FOLFIRI
Enrolled patients, No. 28 75 82
Objective Response, % 79 32 34
Median progression-free survival, months 11 8.5 6.2
Median overall survival, months 21 19.9 17.8
Oncotarget37878www.impactjournals.com/oncotarget
Tailored medical treatments in patients unfit for FIr-B/
FOx intensive regimen
Consecutively evaluated MCRC patients unsuitable, 
due to age and/or comorbidities, to be treated with triplet 
chemotherapy plus targeted agent, in the FIr-B/FOx 
expanded clinical program or to be enrolled in the ongoing 
phase II trial proposing intensive triplet chemotherapy 
plus cetuximab in RAS wild-type disease, were treated 
in clinical practice, with first line medical or surgical 
treatment options, chosen among those in indication for 
MCRC [7], and tailored according to age (< or ≥ 75 years), 
fitness (PS, CIRS), RAS genotype.
From February 2010 to October 2012, 40 patients 
were unfit for FIr-B/FOx intensive regimen, among 72 
consecutive MCRC (56%). Patients’ distribution according 
to age and comorbidities was: young-elderly 22%, old-
elderly 54%; CIRS stage primary 11%, intermediate 40%, 
secondary 42%. Medical treatment regimens were tailored 
according to age and comorbidity status in the individual 
patients. Eighteen patients (49%) were treated with triplet 
regimens; 15 patients (40%) with doublet regimens; 4 
patients (11%) with mono regimens; 3 underwent up-front 
surgery.
At a median follow-up of 8 months, ORR was 37%, 
median PFS was 7 months (1-13+), median OS 13 months 
(1+-23+). Among patients treated with triplet regimens, 
ORR was 37.5%, median PFS 8 months (3-12), median 
OS 12 months (3-23+ months) (Table 3). Among patients 
treated with doublet regimens, ORR was 44%, median 
PFS 8 months (1-13+), median OS 15 months (1+-23+ 
months). PFS and OS were not significantly different 
among MCRC patients treated with triplet regimens 
compared to other first lines (p = 0.947 and p = 0.557, 
respectively), and to doublet regimens (p = 0.885 and 
p = 0.616, respectively). More, PFS and OS were not 
significantly different in non-elderly and young-elderly 
patients compared to old-elderly patients (p = 0.240 and 
p = 0.750, respectively), and in primary/intermediate 
compared to secondary CIRS stage patients (p = 0.494 and 
p = 0.364, respectively).
Among 14 KRAS wild-type patients evaluable for 
activity, ORR was 50%, median PFS 8 months (1+-13+ 
months), median OS 13 months (1+-23+ months). Among 
12 KRAS mutant patients evaluable for activity, ORR 
was 25%, median PFS 6 months (1-11 months), median 
OS 8 months (3-18 months). A significantly different 
PFS (p = 0.043), but not OS, was reported in KRAS 
wild-type compared with mutant patients. Significantly 
worse PFS and OS were reported in c.35 G > A KRAS 
mutant compared to wild-type (p = 0.000, and p = 0.049, 
respectively), and to other mutant patients (p = 0.020, and 
p = 0.048, respectively).
DISCUSSION
Fit young elderly patients, PS<2, treated with 
triplet regimens consisting of chemotherapeutic drugs, 
or BEV addiction to doublets, or doublets plus EGFR-
inhibitors in KRAS wild-type patients, demonstrated 
clinical outcome and safety profile equivalent to younger 
patients [3, 5, 8, 1]. More intensive FIr-B/FOx regimen 
[2, 9, 34] obtained ORR 79%, median PFS 11, median 
OS 21 months in fit young-elderly patients. FIr-B/
FOx was feasible at median rDI 80%. Prevalent G3-4 
toxicities were diarrhea (21%), stomatitis/mucositis 
(11%), asthenia (11%), neutropenia (11%). Good safety 
profile, particularly regarding haematological toxicity, 
could be related to weekly alternating schedule of triplet 
chemotherapy regimen added to bevacizumab. Individual 
LTS were reported in 46% young-elderly patients, mainly 
including diarrhea (69.2%), and significantly more 
represented by LTS-ms compared to LTS-ss (chi square 
3.832, p = 0.05), with respect to non elderly patients. 
Our retrospective exploratory analysis, evaluated in a 
Table 2: Prevalent limiting G3-4 cumulative toxicity in young-elderly MCRC patients
FIr-B/FOx FOLFOXIRI FOLFIRI
Number of patients 28 52 57
NCI-CTC Grade 3 4 3 4 3 4
Diarrhea (%) 21 - 30 35 14 18
Stomatitis/mucositis (%) 11 - 7 8 6 8
Asthenia (%) 11 - 7 8 5 7
Neurotoxicity (%) - - 8 10 - 1
Anemia (%) - - 3 3 1 1
Neutropenia (%) 11 - 32 38 24 28
Febrile neutropenia (%) - - 3 4 2 3
Thrombocytopeny (%) - - 1 2 1 3
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small cohort of MCRC patients that requires further 
prospective validation, showed that intensive FIr-B/FOx 
schedule is equivalently safe and feasible, without severe 
adverse events related to BEV, in young-elderly patients, 
selected by favourable PS, functional and comorbidity 
status, with LTS-ms significantly increased compared to 
LTS-ss, compared to non-elderly patients. Young-elderly 
MCRC patients suitable for intensive FIr-B/FOx regimen 
should be carefully selected based on comorbidity and 
functional status, and monitored for individual safety 
in clinical practice (Table 4). Elderly MCRC patients 
are prevalent and first line medical treatment should 
be selected according to a decision-making process 
integrating the evaluation of patient’s fitness for intensive 
medical treatments with reported increasing effectiveness 
and toxicity.
Retrospective analysis of randomized clinical 
trials showed that doublets CPT-11, or OXP, added to 
fluoropyrimidin in older patients eligible for clinical 
study reported ORR 18-59.4%, PFS 4.9-10.0 months 
and OS 8.5-20.7 months [15-22, 32, 30]. In elderly 
patients, significantly increased PFS up to 9.2-9.3 and 
OS up to 17.4-19.3 months, were reported with BEV 
addition to 5-FU-based chemotherapy [24, 25]. Triplet 
chemotherapeutic drugs or BEV added to doublets 
reached ORR 34.9-45.9%, PFS 7.9-9.3 months and OS 
17.4-20.5 months [25–27]. The positive benefits in terms 
of efficacy and tolerability highlighted by these trials 
represented the main reason that led the international 
scientific societies (NCCN and ESMO) to recommend 
chemotherapy for elderly patients deemed fit for standard 
chemotherapy [45, 46]. In particular, our tailored clinical 
approach, characterized by the evaluation of elderly 
status and/or CIRS (Table 4), and prevalently tailoring 
doublets and triplets in MCRC patients unfit for intensive 
first line FIr-B/FOx, reported ORR 37%, PFS 7 months 
and OS 13 months. PFS and OS were not significantly 
different according to administered treatment regimens, 
triplet versus doublet, elderly status, or CIRS stage. In 
the FOCUS2 trial, evaluating first line OXP addiction 
to 80% dose 5-FU or capecitabine in old-elderly and/or 
frail MCRC patients, ORR was significantly improved 
up to 35%, with PFS 5.8 months [22]. PS was reported 
as significantly related to clinical outcome, regardless of 
treatment: ORR 43.8% vs 32%, PFS 7.6 vs 4.9 months, 
OS 17.3 and 8.5 months, in PS 1 compared to PS 2 
patients, respectively [22]. In the HORG-FOLFOXIRI 
trial, no different clinical outcome was observed in elderly 
versus non-elderly patients; significantly lower clinical 
outcome was reported in patients with PS 2 [31, 32]. Liver 
metastasectomies were reported in 1.3% and 4.4% patients 
in FOLFIRI and FOLFOXIRI arms, respectively [32] and 
can achieve OS 43 months, not significantly different 
from younger patients in the experience of liver resection 
in elderly patients [35]. Morbidity and/or mortality after 
liver surgery were significantly higher in elderly patients 
(8%) [36].
Published studies showed that limiting toxicities 
were not significantly different in elderly patients treated 
with 5-FU or CPT-11 [14–16], slightly increased with 
FOLFOX [21], significantly increased by capecitabine 
(40%), while not by the addition of OXP [22]. Limiting 
diarrhoea was significantly higher with FOLFIRI and 
FOLFOXIRI [29, 30]. PS 2 was significantly associated 
with increased grade 3/4 neutropenia, febrile neutropenia, 
diarrhoea, fatigue, compared with PS 0-1 [30–32]. 
In elderly patients, BEV addition to chemotherapy 
was significantly associated with increased arterial 
thromboembolism [37], while not to other adverse events 
[24–27].
In clinical practice, selection of patients eligible 
for intensive medical treatment and to achieve optimal 
activity and clinical outcome could be performed by 
the evaluation of age, PS, CIRS and careful monitoring 
of individual safety using LTS (Table 4). Patients unfit 
for first line intensive FIr-B/FOx, due to age (≥ 75 
years) and/or comorbidity status, were prevalent (56%), 
mostly elderly (76%), specifically old-elderly (54%), 
prevalently PS 1-2 (59%), intermediate/secondary CIRS 
stage (89%), O/MM disease (79%) [7]. Patients unfit for 
FIr-B/FOx showed worse PFS and OS. No significantly 
higher morbidity, nor mortality rates were showed in 
unfit patients who underwent secondary resection of 
liver metastases, reported as significantly more frequent 
Table 3: Clinical outcome in elderly MCRC patients according to treatment selected by age and CIRS
Medical treatment regimens
FIr-B/FOx Triplet Doublet
Enrolled patients, No. 28 18 15
Elderly patients, No. 28 12 12
Objective Response, % 79 37.5 44
Median progression-free survival, 
months 
11 8 8
Median overall survival, months 21 12 15
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in elderly patients (8%) [36]. In patients unfit for FIr-B/
FOx, a significantly different PFS, while not OS, was 
reported in KRAS wild-type compared to mutant patients. 
More, significantly worse clinical outcome (PFS and 
OS) may be influenced by KRAS c.35 G > A mutant 
genotype, compared to wild-type and/or other mutant, 
confirming that KRAS genotype, and specifically c.35 G 
> A mutant, confers different biological aggressiveness 
[38–41], less effectively overcome by triplet and doublet 
medical treatment regimens conventionally administered 
in clinical practice. A careful decision-making process 
including CIRS and monitoring of individual LTS can be 
used to properly select first line intensive FIr-B/FOx or 
tailored medical treatment in young-elderly patients. In 
unfit MCRC patients, KRAS genotype may significantly 
explain different PFS, and c.35 G > A KRAS mutant a 
significantly worse PFS and OS, compared to wild-type 
and other mutant.
MATERIALS AND METHODS
We revised intensive medical treatment consisting 
of triplet chemotherapy regimens or more intensive 
triplet chemotherapy plus anti-angiogenic drug, 
bevacizumab, in elderly MCRC patients, that we 
previously developed, discussed compared with tailored 
medical regimens selected for unfit MCRC in clinical 
practice [2, 7, 32], and discussed in the scenario of 
therapies proposed for elderly patients. This review 
comprehensively evaluate activity and clinical outcome 
of first-line medical treatment of elderly MCRC patients 
to propose a careful decision-making process including 
age, performance status, and Cumulative Index Rating 
Scale (CIRS) and monitoring of individual limiting 
toxicity syndromes (LTS), to properly select first line 
intensive or tailored medical treatment in young-elderly 
and elderly patients [7, 8, 2, 9], and aim to underline the 
prognostic relevance of KRAS genotype, and specifically 
the prevalent KRAS c.35 G > A mutant status, that can 
discriminate significantly different clinical outcome 
particularly in unfit MCRC patients.
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